anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intradialytic hypotension (IDH) is a common complication during hemodialysis (HD) which accounts up to 5 to 30 percent of all dialysis treatment and is associated with increased morbidity and mortality. The etiology of IDH is multifactorial, but intravascular volume depletion, autonomic neuropathy, and decreased cardiac reserve were the main factors. Several approaches were utilized to prevent IDH including adaptation of dialysis prescriptions, lengthening in dialysis time, avoiding food intake during dialysis, as well as limiting interdialytic sodium intake and administration of vasoconstrictor agents. However, it remains necessary to seek novel effective and safe inventions for IDH. To date, no studies have been done to evaluate the effectiveness of acupuncture and traditional moxibustion during HD for safety reasons (eg: risk of bleeding, burns and unpleasant smell). Therefore, the heating device appears to be a non-invasive and safe method for treating IDH. The investigators conduct a clinical trial using infrared heating devices without direct contact to the skin on low temperatures (56±8℃) in treating patients with IDH. 30 eligible participants diagnosed with IDH will be enrolled and divided into Group 1 and Group 2. Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus "HEALTHY BOX" Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks. For Group 1, each subject will receive Treatment 1# first, for Group 2, Treatment 2# will be received first. Then, it takes 2-week washout period with regular dialysis 3 times per week and make Group 1 and Group 2 crossover. Outcomes will include blood pressure changes, nursing intervention frequencies, IDH frequencies, the degree of cold intolerance, the degree of fatigue after dialysis and recovery time from fatigue after dialysis, the percentage of target ultrafiltration achieved and blood biochemistry. Data will be collected at the beginning of the study (baseline), end of Treatment 1 # , and end of Treatment 2#. Subjective questionnaires will be collected before and after each treatment period. The difference of evaluation scores between baseline and post-treatment will be analyzed using generalized linear mixed model. A value of P \< 0.05 will be regarded as statistically significant for the above statistical analyses.
The SonoCloud-9 (SC9) device will be implanted in the skull bone window upon completion of tumor resection and routine craniotomy. Carboplatin (CBDCA) will be administered intravenously prior to sonication. The CBDCA/SC9 treatment will be repeated every 3 weeks (depending on patient's tolerability) until disease progression or as clinically indicated. Administration of up to 7 cycles is planned.
Naropin ® Injection contains ropivacaine HCl which is a member of the amino amide class of local anesthetics. Naropin Injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. Sodium hydroxide and/or hydrochloric acid may be used for pH adjustment. It is administered parenterally.

Ropivacaine HCl is chemically described as S-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride monohydrate. The drug substance is a white crystalline powder, with the following structural formula:

At 25°C ropivacaine HCl has a solubility of 53.8 mg/mL in water, a distribution ratio between n-octanol and phosphate buffer at pH 7.4 of 14:1 and a pKa of 8.07 in 0.1 M KCl solution. The pKa of ropivacaine is approximately the same as bupivacaine (8.1) and is similar to that of mepivacaine (7.7). However, ropivacaine has an intermediate degree of lipid solubility compared to bupivacaine and mepivacaine.

Naropin Injection is preservative-free and is available in single dose containers in 2 (0.2%), 5 (0.5%), 7.5 (0.75%) and 10 mg/mL (1%) concentrations. The specific gravity of Naropin Injection solutions range from 1.002 to 1.005 at 25°C.
Online training intervention: A non-adaptive placebo version of Cogmed RM working memory training. Tasks are fixed at a low-difficulty practice level (three to-be-remembered items) and do not increase in difficulty over the course of the intervention. Participants complete 35-45 minutes of active placebo training per day, 5 days a week for 5 weeks.
The invention discloses a Radix Scrophulariae and licorice submicron powder having a chicken immunity enhancement effect, and a preparation method thereof. The submicron powder is composed of Radix Astragali, Radix Scrophulariae, licorice, Divaricate Saposhnikovia Root and Rhizoma Atractylodis Macrocephalae. The preparation method comprises the following steps: respectively picking the above components, removing impurities, carrying out coarse crushing, and screening by a 24 mesh sieve; weighing the obtained crude powders according to formula proportions, mixing, and baking in a 60DEG C drying box to the water content of below 7%; and crushing the obtained dried mixture in a rod mill, sending to a special bidirectional airflow screener through a fan for 300 mesh sieve screening, conveying the screened powder to a cyclone collector to obtain the Radix Scrophulariae and licorice submicron powder, collecting the unscreened powder by a funnel, and conveying the collected powder to the rod mill through a pipeline for secondary crushing. The particle size of 90% of the processed powder is less than 30mum. The Radix Scrophulariae and licorice submicron powder has the advantages of reasonable formula, small addition, undoubted effects, easy method implementation, and large-scale production. The preparation method enables the whole preparation process to be carried out at normal temperature and the cell wall breaking rate to be improved; and the special bidirectional airflow screener simplifies the preparation technology of the Radix Scrophulariae and licorice submicron powder.
KCNA1 is the coding gene for Kv1.1 voltage-gated potassium-channel α subunit. Three variants of KCNA1 have been reported to manifest as paroxysmal kinesigenic dyskinesia (PKD), but the correlation between them remains unclear due to the phenotypic complexity of KCNA1 variants as well as the rarity of PKD cases. Using the whole exome sequencing followed by Sanger sequencing, we screen for potential pathogenic KCNA1 variants in patients clinically diagnosed with paroxysmal movement disorders and identify three previously unreported missense variants of KCNA1 in three unrelated Chinese families. The proband of one family (c.496G>A, p.A166T) manifests as episodic ataxia type 1, and the other two (c.877G>A, p.V293I and c.1112C>A, p.T371A) manifest as PKD. The pathogenicity of these variants is confirmed by functional studies, suggesting that p.A166T and p.T371A cause a loss-of-function of the channel, while p.V293I leads to a gain-of-function with the property of voltage-dependent gating and activation kinetic affected. By reviewing the locations of PKD-manifested KCNA1 variants in Kv1.1 protein, we find that these variants tend to cluster around the pore domain, which is similar to epilepsy. Thus, our study strengthens the correlation between KCNA1 variants and PKD and provides more information on genotype-phenotype correlations of KCNA1 channelopathy.
Teratogenic Effects:Pregnancy Category C: As with other corticosteroids, budesonide was teratogenic and embryocidal in rabbits and rats. Budesonide produced fetal loss, decreased pup weights, and skeletal abnormalities at subcutaneous doses of 25 mcg/kg in rabbits (approximately 0.05 times the maximum recommended human dose on a body surface area basis) and 500 mcg/kg in rats (approximately 0.5 times the maximum recommended human dose on a body surface area basis).

There are no adequate and well-controlled studies in pregnant women. Budesonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects: Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully observed.
PURPOSE:To obtain an excellent antitumor drug composition by culturing in medium a recombinant microorganism cell transformed with the recombinant plasmid containing a specific DNA region. CONSTITUTION:A double chain DNA region composed of a single chain DNA and another complementary single chain DNA exhibiting a base sequence expressed by formula II coding a boiactive polypeptide exhibiting the amino acid sequence expressed by formula I or a polypeptide bonding with Met at amino terminal is contained in a recombinant plasmid (A) (e.g. antitumor-active polypeptide gene-manifesting type plasmid pTNF 496). Next, the A component is introduced into Escherichia coli and a transformant strain (B) is obtained. Then the B-strain is aerobically cultured in a medium containing glucose, etc., at about 37 deg.C for 2-36hr to obtain a cultured substance (C). Thus, the C- component is centrifuged and the resultant microorganismic cells are suspended in phosphoric acid buffer, etc., then subjected to a supersonic treatment, thus the resultant cell ligate is purified with electrophoretic method, etc., to produce a bioactive polypeptide exhibiting the amino acid sequence expressed by formula I.
The NHLBI Stem Cell Allotransplantation Program is researching methods to improve immunity against infectious organisms following allogeneic stem cell transplantation (SCT). We are particularly interested in cytomegalovirus (CMV), which can cause serious problems in patients following transplantation. In the future, we hope to design ways to improve immune responses to CMV in transplant recipients, such as vaccinating transplant donors and/or patients against this virus. In order to characterize the effect of any such intervention on CMV immunity, we first need to better understand CMV immune responses in normal, healthy persons. This involves designing and validating an in vitro assay, which can reliably and consistently detect immune responses against CMV. Furthermore, we hope to define the temporal variability that exists in CMV responses in healthy individuals, which is essential for the design and implementation of all future studies. We plan to collect blood samples from 20 normal volunteers who have been previously exposed to CMV (CMV seropositive individuals). Eligible individuals will be asked to donate blood on five occasions, once a week for four weeks and a fifth time, two months later. Eligible individuals must be 18-65 years of age, otherwise healthy, and seropositive for CMV exposure.
The invention relates to a tea tree essential oil and ethanol double-disinfection and no-wash hand sanitizer and a preparation method thereof. The no-clean hand sanitizer contains ethanol, and also contains tea tree extract and aloe extract; the content of the ethanol is 60-75% by mass ratio. Further, the oil-in-water emulsion also contains glycerol, isopropyl myristate, benzophenone-4, a dissolving promoter and a thickening agent. The invention also provides a preparation method of the no-clean hand sanitizer. The invention contains various antibacterial components, takes ethanol as a main bactericide and takes tea tree extract as an auxiliary, and has broad-spectrum antibiotic sterilization and disinfection effects. The aloe fresh leaf extract also contains the aloe fresh leaf extract which has the functions of moisturizing and sun screening, and has the plant skin care function while long-acting sterilization.
Epigenetic deregulation is strongly associated with tumor progression. The identification of natural tumor suppressors to overcome cancer metastasis is urgent for cancer therapy. We investigate whether myeloid/lymphoid or mixed-lineage leukemia translocated (MLLT) family members contribute to breast cancer progression and found that high MLLT6 expression predicted a better prognosis and that gradually decreased MLLT6 expression was accompanied by breast cancer malignancy. MLLT6 was downregulated by hypoxia-induced enrichment of DNMT1 at the MLLT6 promoter. The results of in vitro functional experiments indicated that MLLT6 depletion promoted colony formation and cell migration, probably by hampering apoptosis. RNA profiling revealed that the apoptotic pathway was downregulated following stable knockdown of MLLT6. DNA damage-inducible transcript 3/4 (DDIT3/4) were among the top 10 downregulated genes and may have expression patterns similar to that of MLLT6. Restoring DDIT3/4 expression in cells with MLLT6 depletion blocked colony formation and cell migration and attenuated the successful colonization of breast cancer cells in vivo. We also determined that the transcription factor activating transcription factor 2 is a binding partner of MLLT6 and participates in the MLLT6/ATF2 axis, which was reinforced by inhibition of AKT signaling, in turn inducing DDIT3/4 expression by establishing an active chromatin structure at the DDIT3/4 gene promoters. As MLLT6 promotes breast cancer cell apoptosis by inducing DDIT3/4 expression during metastasis, it could be a novel tumor suppressor. Implications: Control of MLLT6 expression via inhibition of PI3K/AKT kinase activity is a potential therapeutic approach for the management of metastatic breast cancer.
NEW MATERIAL:The compound of formula I [A is residue of 1,2-diamino-2- methylbutane, 1,2-diamino-2-ethylbutane, 1-amino-aminomethyl-cyclopentane, or 1-amino-1-aminomethylcyclohexane (abbreviated as a, b, c and d, respectively); when A is a, X is halogen; when A is b or c, two X groups together form group of formula II or III when A is d, two X groups together form the group of formula II or IV (B is b and Y is OH or halogen or B is c and Y is halogen; Z is halogen)]. EXAMPLE:cis-Dichloro-1,2-diamino-2-methylbutaneplatinum. USE:A carcinostatic agent having excellent water-solubility, etc. PREPARATION:A dihalogenoplatinum complex is produced e.g. by reacting potassium haloplatinoate with a diamine. The complex is treated with silver nitrate and made to react with a carboxylic acid to obtain a carboxylate complex. A tetrahalogen compound can be produced by treating the dihalogenoplatinum complex with hydrogen peroxide and reacting with a hydrogen halide.
The coronavirus disease 2019 (COVID-19) was first introduced in December 2019, which is known as severe acute respiratory syndrome caused by coronavirus-2 (SARS-CoV-2) that is a serious and life-threatening disease. Although pneumonia is the most common manifestation of COVID-19 and was initially introduced as a respiratory infection, in fact, the infection of COVID-19 is a subset of complications and damage to various organs. There are several reports of cardiac involvement with COVID-19. A wide range of cardiac complications may occur following COVID-19 infection, including systolic heart failure, myocarditis, pericarditis, atrial and ventricular arrhythmias, and thromboembolic events. There are various hypotheses about the pathophysiology of cardiovascular involvement by this virus. At the top of these hypotheses is the release of cytokines to the heart. Although there are other assumptions, considering that one of the causes of death in patients with COVID-19 is arrhythmia. It is necessary to know correctly about its pathophysiology and etiology. Therefore, in this study, we have reviewed the articles of recent years in the field of pathophysiology and etiology of arrhythmia in patients with COVID-19 infection. The purpose of this study was to provide a basis for a correct and more comprehensive understanding of the pathogenesis of arrhythmia in patients with COVID-19 infection.
Equations for predicting body mass from stature and bi-iliac (maximum pelvic) breadth have been developed, but have had variable success when applied to living or recently deceased individuals, calling into question their general applicability. Here we test these equations on a large, ethnically diverse sample. Skeletal and anthropometric data for 507 recently deceased Indigenous, Hispanic, and non-Hispanic White adults were obtained from the New Mexico Decedent Image Database. The body mass of individuals with a "normal" body mass index (BMI = 18.5-24.9) is very accurately predicted, with an average directional bias of about 1% and an average random error of less than 8%. Underweight individuals (BMI < 18.5) are overpredicted, while overweight (BMI = 25-29.9) and especially obese (BMI≥30) individuals are underpredicted. Within BMI categories, there is a strong and isometric relationship between predicted and true body mass. Individual body mass prediction errors using the stature/bi-iliac method are mainly dependent on variation in BMI. Because earlier humans were more likely to fall within or close to the normal BMI range, the equations should be applicable, on an individual basis, in archeological and paleontological contexts. Because of the prevalence of obesity in many modern populations, these equations are not applicable in a general forensic context. We derive new equations from nonobese individuals in our sample (n = 338), which produce reasonable average prediction errors. If obese individuals can be identified using other skeletal parameters, these equations may be useful in estimating body mass in nonobese forensic cases.
An Athyrium multidentatum(Doll.) Ching skincare wine and its production method. According to the invention, Athyrium multidentatum(Doll.) Ching, Phaseolus calcaratus, Pharbitis(L.)Choisy., Angelica sinensis, batryticated silkworms, dittany bark, Common Bletilla Pseudobulb powder, Flos rosae rugosae, peach blossom, peony, Globe Amaranth and red dates are used as main raw materials. The Athyrium multidentatum(Doll.) Ching skincare wine has health-care and skincare functions, has an effect of tranquilizing by nourishing the heart, has the advantage of fast effectiveness, is pure natural, has no toxic or side effect, has good adjuvant therapy for treating main symptoms such as stain and the like, and is applicable to be taken at home. The invention provides the Athyrium multidentatum(Doll.) Ching skincare wine and its production method.
The participants in this arm were administered the following intervention: The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
Bupropion is associated with seizures in approximately 0.4% (4/1,000) of patients treated at doses up to 450 mg/day. This incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold. This relative risk is only an approximate estimate because no direct comparative studies have been conducted. The estimated seizure incidence for bupropion hydrochloride tablets increases almost tenfold between 450 and 600 mg/day, which is twice the usually required daily dose (300 mg) and one and one-third the maximum recommended daily dose (450 mg). Given the wide variability among individuals and their capacity to metabolize and eliminate drugs this disproportionate increase in seizure incidence with dose incrementation calls for caution in dosing.

During the initial development, 25 among approximately 2,400 patients treated with bupropion hydrochloride tablets experienced seizures. At the time of seizure, 7 patients were receiving daily doses of 450 mg or below for an incidence of 0.33% (3/1,000) within the recommended dose range. Twelve patients experienced seizures at 600 mg/day (2.3% incidence); 6 additional patients had seizures at daily doses between 600 and 900 mg (2.8% incidence).

A separate, prospective study was conducted to determine the incidence of seizure during an 8-week treatment exposure in approximately 3,200 additional patients who received daily doses of up to 450 mg. Patients were permitted to continue treatment beyond 8 weeks if clinically indicated. Eight seizures occurred during the initial 8-week treatment period and 5 seizures were reported in patients continuing treatment beyond 8 weeks, resulting in a total seizure incidence of 0.4%.

The risk of seizure appears to be strongly associated with dose. Sudden and large increments in dose may contribute to increased risk. While many seizures occurred early in the course of treatment, some seizures did occur after several weeks at fixed dose. Bupropion hydrochloride tablets should be discontinued and not restarted in patients who experience a seizure while on treatment.

The risk of seizure is also related to patient factors, clinical situations, and concomitant medications, which must be considered in selection of patients for therapy with bupropion hydrochloride tablets.

  * Patient factors: Predisposing factors that may increase the risk of seizure with bupropion use include history of head trauma or prior seizure, central nervous system (CNS) tumor, the presence of severe hepatic cirrhosis, and concomitant medications that lower seizure threshold.
  * Clinical situations: Circumstances associated with an increased seizure risk include, among others, excessive use of alcohol or sedatives (including benzodiazepines); addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; and diabetes treated with oral hypoglycemics or insulin.
  * Concomitant medications: Many medications (e.g., antipsychotics, antidepressants, theophylline, systemic steroids) are known to lower seizure threshold.
An accelerometer based on the measurement of Casimir force fluctuations is described. The accelerometer comprises a sealed housing containing a vacuum or a liquid, a piezoelectric plate fixed with the sealed housing, and a mass moveable within the sealed housing located in proximity to the piezoelectric plate. The moveable mass and the piezoelectric plate each have conductive surfaces which are located from each other at a distance which creates a Casimir Effect between the movable mass and the piezoelectric plate. Fluctuations in acceleration of the moveable mass cause fluctuations in the Casimir force on the piezoelectric plate.  The acceleration fluctuations cause fluctuations in an electric output of the piezoelectric plate. The fluctuations in electric output are measured and used to calculate an acceleration and direction of movement of the accelerometer or a host device in which the accelerometer is carried.